Merck's Keytruda Shows Clinical Benefit in Post-Surgery Kidney Cancer Setting

Loading...
Loading...
  • Merck & Co MRK announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment in a subset of patients with renal cell carcinoma (RCC).
  • The trial included RCC patients at intermediate-high or high risk of recurrence following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions.
  • The results will be presented at the virtual American Society of Clinical Oncology meeting.
  • In patients with clear-cell renal cell carcinoma, Keytruda treatment after surgery slashed the risk of the disease returning or death by 32% compared with placebo.
  • At the two-year mark, 77.3% of patients who got Keytruda in Phase 3 Keynote-564 trial remained alive and disease-free, compared to 68% in the placebo group.
  • Overall survival (OS) was too early to determine at the data cutoff. Still, the company did have a “favorable trend” in the early readout, with Keytruda cutting the risk of death by 46% over placebo.
  • However, the median disease-free survival data were immature at this point.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: MRK shares closed at $73.91 on Thursday.
Posted In: BiotechNewsHealth CareFDAGeneralBriefsKidney CancerPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...